Custom audience development vs syndicated segments.
Do you have the budget to simply outspend your competitor? If you’re like most marketers, the answer is no. So when it comes to your media dollars, if you’re not doing anything different than your closest competitors, you are on a treadmill with little chance to get off. Your business is unique. Lean into it!
We all know the importance of audience targeting. When budget matters, it’s critical to make sure your media spend is delivered to an audience uniquely qualified for your business. Everything else is waste.
To solve this, many brands and agencies turn to 3rd party syndicated audience vendors who pre-package healthcare audience categories and offer them on the open exchange. And these syndicated audiences are typically very good. They are already built, already priced, and already loaded into your DSP. So they’re easy too.
But a segment built for the average brand in a category will, by design, perform like the average brand in that category. And if that’s where everyone turns, what should be a point of differentiation for you, becomes a point of parity. You’re back on the treadmill!
What "off the shelf" really means
A syndicated health audience is built once and sold to many. "Type 2 Diabetes Sufferers." "Interested in Eczema." These modeled look-alikes are built to a standard definition, then scaled to hit a size that sells.
That last part is the important bit. A segment has to be big enough to be useful to lots of buyers, which pushes the definition broad. Broad is fine if you sell glucose test strips. It is a problem if you are launching a therapy for a specific sub-population of patients who have already tried and failed two lines of treatment.
Consider what comes within a typical open-market segment:
Someone else's definition. The vendor decided who counts as a "heart patient." You inherit that choice without seeing it.
A category lens, not a therapy lens. The segment describes a condition. Your brand treats a specific patient, at a specific stage, under a specific label.
Shared supply. Your competitors can buy the identical audience. Whatever edge it offers, it offers to everyone.
Where the gap is widest: launches and new indications
If you are an established brand in a mature category, a syndicated segment may work just fine. But at launch, or when an existing brand earns a new indication, it can be less effective for your use case.
The audience you need did not exist when the segment was built. A new indication creates a new patient definition overnight. No vendor has a ready-made segment for "adults with moderate-to-severe disease who have had an inadequate response to first-line therapy" because, until your approval, nobody was selling to that person.
The label is the definition. Your target is set by inclusion criteria, contraindications, prior treatment history, and often a specific diagnostic or procedural pathway. A condition-level segment cannot see any of that. It finds people with the disease, not people your therapy is indicated for.
Specificity is the whole story. A therepy for relapsed or refractory multiple myeloma is not the same opportunity as "blood cancer." A transcatheter valve procedure is not the same patient as "heart health enthusiast." The closer your brand is to a specific procedure, line of therapy, or patient journey, the more a generic audience dilutes your spend with people who will never qualify.
Launch budgets are the least forgiving. The first 12 to 18 months set the trajectory for a brand. Spending them on a look-alike of a look-alike is the most expensive kind of waste, because the opportunity cost compounds.
What custom audience development looks like
Custom audience development starts with your unique area of clinical focus. Instead of asking "which existing segment is closest?", it asks "who exactly is this therapy for, and how do we find them?" We think about it in three questions: Who, When, and How.
Who: define the patient the way your label does. Using de-identified, privacy-compliant claims data, we translate your indication into a clinical definition: the diagnosis codes, procedures, prior therapies, and care patterns that describe an eligible patient. That definition trains a predictive model, which scores households on their likelihood of matching it. The result is an audience built for one brand and one indication. Yours.
When: find the moment, not just the person. Claims data is powerful but backward-looking. It tells you who has the condition, not who is ready to act. Layering in behavioral and contextual signals, like active research on a condition or treatment, helps identify when a qualified patient is in-market and most receptive.
How: put the message where it lands. Precision targeting earns its keep only if the message is actually seen, read, and remembered. Once you know who and when, you can afford to invest in higher-impact channels, including physical media, against a smaller, better-qualified audience instead of spreading thin impressions across a broad one.
Best of all, custom audience development is built for your brand. Your competitor cannot buy the same audience next quarter
The real cost of a generic audience
The metric that matters is not cost per piece or CPM. It is cost per qualified patient reached. A cheap impression delivered to someone outside your label is not cheap. It is pure waste.
Consider a simple, illustrative comparison. The numbers below are hypothetical, chosen to show the math, not benchmarks.
| Off-the-shelf | Custom Model | |
|---|---|---|
| Households reached | 1,000,000 | 200,000 |
| Share who actually fit the label | 5% | 40% |
| Qualified households reached | 50,000 | 80,000 |
| Cost per household (incl. data) | $0.75 | $0.90 |
| Total spend | $750,000 | $180,000 |
| Cost per qualified household | $15.00 | $2.25 |
The custom audience costs more per contact and still wins by a wide margin. It reaches more of the right people for less than a quarter of the budget. That freed-up spend can go toward more touches against the same qualified patients, which matters in a category where it typically takes several exposures to move someone to action.
Your brand deserves its own audience
Your clinical team spent years defining exactly who your therapy helps. Your marketing should honor that precision, not round it off to the nearest available segment.